Patient Communities Rare disease patients often report feeling lonely and isolated due to the lack of awareness and understanding surrounding their disease. Patients are sparsely located all over the world and it can be difficult to identify and connect with one...
Nitisinone Nitisinone Nitisinone is now officially licensed to treat AKU in the European Union. In the UK, patients who attend the National AKU Centre are prescribed 2mg daily.¹ Clinical research has shown that that nitisinone reduced HGA levels by up to 95%.² From...
History of AKU The discovery of AKU AKU was first described as an inherited disease by Sir Archibald Garrod¹ in 1902. Sir Archibald was a true pioneer – relying upon simple observations to understand fundamental aspects of human biology. He was an Edwardian doctor who...
Our Staff Staff Nick Sireau CEO & Chairman of the Trustees Ever since Nick’s sons were diagnosed with AKU, he has been involved with the society. When it was set up in 2003, Nick became a trustee and has served as CEO since 2010. Now, as Chairman of the trustees,...
AKU Privacy Policy Registered in England and Wales Company Ltd. by Guarantee No. 0481412A charity registered in England and Wales (no. 11001052) Updated on 25th May 2020 Your privacy is important to the AKU Society. This privacy statement provides information about...
